238 related articles for article (PubMed ID: 31446807)
1. Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly.
Beugeling M; De Zee J; Woerdenbag HJ; Frijlink HW; Wilschut JC; Hinrichs WLJ
Expert Rev Vaccines; 2019 Sep; 18(9):935-950. PubMed ID: 31446807
[No Abstract] [Full Text] [Related]
2. Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates.
Isaacs A; Cheung STM; Thakur N; Jaberolansar N; Young A; Modhiran N; Bailey D; Graham SP; Young PR; Chappell KJ; Watterson D
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696372
[TBL] [Abstract][Full Text] [Related]
3. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
4. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.
Esposito S; Di Pietro G
Future Microbiol; 2016 Oct; 11():1479-1490. PubMed ID: 27750448
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
[TBL] [Abstract][Full Text] [Related]
7. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model.
Blanco JCG; Pletneva LM; McGinnes-Cullen L; Otoa RO; Patel MC; Fernando LR; Boukhvalova MS; Morrison TG
Nat Commun; 2018 May; 9(1):1904. PubMed ID: 29765035
[TBL] [Abstract][Full Text] [Related]
9. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
[TBL] [Abstract][Full Text] [Related]
10. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Rossey I; Saelens X
Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
[No Abstract] [Full Text] [Related]
11. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the development of subunit-based RSV vaccines.
Jaberolansar N; Toth I; Young PR; Skwarczynski M
Expert Rev Vaccines; 2016; 15(1):53-68. PubMed ID: 26506139
[TBL] [Abstract][Full Text] [Related]
13. Current progress on development of respiratory syncytial virus vaccine.
Chang J
BMB Rep; 2011 Apr; 44(4):232-7. PubMed ID: 21524347
[TBL] [Abstract][Full Text] [Related]
14. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation.
Stegmann T; Kamphuis T; Meijerhof T; Goud E; de Haan A; Wilschut J
Vaccine; 2010 Aug; 28(34):5543-50. PubMed ID: 20600502
[TBL] [Abstract][Full Text] [Related]
15. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z
Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells.
Nallet S; Amacker M; Westerfeld N; Baldi L; König I; Hacker DL; Zaborosch C; Zurbriggen R; Wurm FM
Vaccine; 2009 Oct; 27(46):6415-9. PubMed ID: 19559121
[TBL] [Abstract][Full Text] [Related]
17. Subunit and virus-like particle vaccine approaches for respiratory syncytial virus.
Morrison TG; Walsh EE
Curr Top Microbiol Immunol; 2013; 372():285-306. PubMed ID: 24362695
[TBL] [Abstract][Full Text] [Related]
18. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
Taleb SA; Al Thani AA; Al Ansari K; Yassine HM
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1817-1827. PubMed ID: 29876771
[TBL] [Abstract][Full Text] [Related]
19. Vaccines against respiratory syncytial virus: The time has finally come.
Graham BS
Vaccine; 2016 Jun; 34(30):3535-41. PubMed ID: 27182820
[TBL] [Abstract][Full Text] [Related]
20. Strategic priorities for respiratory syncytial virus (RSV) vaccine development.
Anderson LJ; Dormitzer PR; Nokes DJ; Rappuoli R; Roca A; Graham BS
Vaccine; 2013 Apr; 31 Suppl 2(Suppl 2):B209-15. PubMed ID: 23598484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
